{"id":"https://openalex.org/W2415618052","doi":"https://doi.org/10.1002/cpdd.285","title":"Pharmacokinetic Evaluation of CYP3A4\u2010Mediated Drug\u2010Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults","display_name":"Pharmacokinetic Evaluation of CYP3A4\u2010Mediated Drug\u2010Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults","publication_year":2016,"publication_date":"2016-06-08","ids":{"openalex":"https://openalex.org/W2415618052","doi":"https://doi.org/10.1002/cpdd.285","mag":"2415618052","pmid":"https://pubmed.ncbi.nlm.nih.gov/27273461","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5298035"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.285","doi":"https://doi.org/10.1002/cpdd.285","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.285","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.285","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.285","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110572749","display_name":"Robert W. Townsend","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robert Townsend","raw_affiliation_strings":["Astellas Pharma Global Development, Inc, Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Global Development, Inc, Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Albert Dietz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103137","display_name":"Spaulding Clinical Research (United States)","ror":"https://ror.org/01bg37c61","country_code":"US","type":"company","lineage":["https://openalex.org/I4210103137"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Albert Dietz","raw_affiliation_strings":["Spaulding Clinical Research, LLC, West Bend, WI, USA","Fellow of the American College of Clinical Pharmacology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Spaulding Clinical Research, LLC, West Bend, WI, USA","institution_ids":["https://openalex.org/I4210103137"]},{"raw_affiliation_string":"Fellow of the American College of Clinical Pharmacology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040313726","display_name":"Christine Hale","orcid":"https://orcid.org/0000-0002-3600-4607","observed_orcids":["https://orcid.org/0000-0002-3600-4607"]},"institutions":[{"id":"https://openalex.org/I60638368","display_name":"Covance (United States)","ror":"https://ror.org/02hhsqf45","country_code":"US","type":"company","lineage":["https://openalex.org/I60638368"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine Hale","raw_affiliation_strings":["Covance Clinical Research, Madison, WI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance Clinical Research, Madison, WI, USA","institution_ids":["https://openalex.org/I60638368"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021184224","display_name":"Shahzad Akhtar","orcid":"https://orcid.org/0000-0003-4081-1169","observed_orcids":["https://orcid.org/0000-0003-4081-1169"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shahzad Akhtar","raw_affiliation_strings":["Astellas Pharma Global Development, Inc, Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Global Development, Inc, Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029494840","display_name":"Donna L. Kowalski","orcid":"https://orcid.org/0000-0003-2025-8474","observed_orcids":["https://orcid.org/0000-0003-2025-8474"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donna Kowalski","raw_affiliation_strings":["Astellas Pharma Global Development, Inc, Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Global Development, Inc, Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051642990","display_name":"Christopher Lademacher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Lademacher","raw_affiliation_strings":["Astellas Pharma Global Development, Inc, Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Global Development, Inc, Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061427649","display_name":"Kenneth C. Lasseter","orcid":"https://orcid.org/0000-0001-8175-2199","observed_orcids":["https://orcid.org/0000-0001-8175-2199"]},"institutions":[{"id":"https://openalex.org/I4210123890","display_name":"Clinical Pharmacology of Miami","ror":"https://ror.org/02wvtac27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210123890"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Lasseter","raw_affiliation_strings":["Clinical Pharmacology of Miami, Inc, Miami, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology of Miami, Inc, Miami, FL, USA","institution_ids":["https://openalex.org/I4210123890"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050213128","display_name":"Helene Pearlman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helene Pearlman","raw_affiliation_strings":["Astellas Pharma Global Development, Inc, Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Global Development, Inc, Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080415960","display_name":"Diane Rammelsberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Diane Rammelsberg","raw_affiliation_strings":["Randstad Pharma, Deerfield, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Randstad Pharma, Deerfield, IL, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110213572","display_name":"Anne H. Schmitt\u2010Hoffmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141406","display_name":"Basilea Pharmaceutica (Switzerland)","ror":"https://ror.org/04n4q2213","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210141406"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Anne Schmitt\u2010Hoffmann","raw_affiliation_strings":["Basilea Pharmaceutica International Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basilea Pharmaceutica International Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I4210141406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102397176","display_name":"Takao Yamazaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Takao Yamazaki","raw_affiliation_strings":["Astellas Pharma Global Development, Inc, Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Global Development, Inc, Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015217929","display_name":"Amit V. Desai","orcid":"https://orcid.org/0000-0001-7394-3606","observed_orcids":["https://orcid.org/0000-0001-7394-3606"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amit Desai","raw_affiliation_strings":["Astellas Pharma Global Development, Inc, Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Global Development, Inc, Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5110572749"],"corresponding_institution_ids":["https://openalex.org/I4210165171"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":8.9942,"has_fulltext":true,"cited_by_count":115,"citation_normalized_percentile":{"value":0.98962246,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":99},"biblio":{"volume":"6","issue":"1","first_page":"44","last_page":"53"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9136000275611877,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9136000275611877,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10150","display_name":"Antifungal resistance and susceptibility","score":0.07670000195503235,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/isavuconazole","display_name":"isavuconazole","score":1.0},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.9409999847412109},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9860000014305115},{"id":"https://openalex.org/keywords/rifampicin","display_name":"rifampicin","score":0.9229999780654907},{"id":"https://openalex.org/keywords/ketoconazole","display_name":"ketoconazole","score":0.9990000128746033},{"id":"https://openalex.org/keywords/midazolam","display_name":"midazolam","score":0.9950000047683716},{"id":"https://openalex.org/keywords/triazole-antifungals","display_name":"triazole antifungals","score":0.8920000195503235},{"id":"https://openalex.org/keywords/cyp3a4-inducers","display_name":"CYP3A4 inducers","score":0.7059999704360962},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.5569999814033508},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7070000171661377},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.4950000047683716}],"concepts":[{"id":"https://openalex.org/C2781064554","wikidata":"https://www.wikidata.org/wiki/Q407883","display_name":"Ketoconazole","level":3,"score":0.9251570701599121},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.8150953054428101},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7131431698799133},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.693172812461853},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6718369126319885},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5907169580459595},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.47898149490356445},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.45299315452575684},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4424772262573242},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.316203236579895},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.3123626410961151},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.14043349027633667},{"id":"https://openalex.org/C2779548794","wikidata":"https://www.wikidata.org/wiki/Q578726","display_name":"Antifungal","level":2,"score":0.060781002044677734},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007654","descriptor_name":"Ketoconazole","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008874","descriptor_name":"Midazolam","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D009640","descriptor_name":"Norethindrone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D012293","descriptor_name":"Rifampin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/cpdd.285","doi":"https://doi.org/10.1002/cpdd.285","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.285","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.285","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5298035","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5298035","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Drug Dev","raw_type":"Text"},{"id":"pmid:27273461","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27273461","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1002/cpdd.285","doi":"https://doi.org/10.1002/cpdd.285","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.285","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.285","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320326120","display_name":"Basilea Pharmaceutica","ror":"https://ror.org/04n4q2213"},{"id":"https://openalex.org/F4320332563","display_name":"Astellas Pharma Global Development","ror":"https://ror.org/05pw69n24"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2415618052.pdf","grobid_xml":"https://content.openalex.org/works/W2415618052.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1813635169","https://openalex.org/W1919380120","https://openalex.org/W1968954779","https://openalex.org/W1996847287","https://openalex.org/W2015677019","https://openalex.org/W2030791966","https://openalex.org/W2037989399","https://openalex.org/W2055442525","https://openalex.org/W2076565275","https://openalex.org/W2084285189","https://openalex.org/W2099294595","https://openalex.org/W2107794472","https://openalex.org/W2114954734","https://openalex.org/W2152082520","https://openalex.org/W2189861011","https://openalex.org/W2296337564","https://openalex.org/W2410678768","https://openalex.org/W2463913953","https://openalex.org/W2487631607"],"related_works":["https://openalex.org/W2411893516","https://openalex.org/W3159827624","https://openalex.org/W4411378035","https://openalex.org/W2487631607","https://openalex.org/W1563894087","https://openalex.org/W2086139063","https://openalex.org/W1989463701","https://openalex.org/W2004576165","https://openalex.org/W2901761577","https://openalex.org/W2047990326"],"abstract_inverted_index":{"Abstract":[0],"This":[1],"report":[2],"describes":[3],"the":[4,10,13,53],"phase":[5],"1":[6],"trials":[7],"that":[8,188],"evaluated":[9],"metabolism":[11,28],"of":[12,33,71,121,197],"novel":[14],"triazole":[15],"antifungal":[16],"isavuconazole":[17,35,50,72,87,189],"by":[18,61,67,97,153],"cytochrome":[19],"P450":[20],"3A4":[21],"(CYP3A4)":[22],"and":[23,63,95,99,147,156,172,176,194],"isavuconazole's":[24],"effects":[25],"on":[26],"CYP3A4\u2010mediated":[27],"in":[29,166],"healthy":[30],"adults.":[31],"Coadministration":[32],"oral":[34,41,78,122],"(100":[36],"mg":[37,44,74,81,106,115],"once":[38,45,116],"daily)":[39,117],"with":[40,77,118],"rifampin":[42],"(600":[43],"daily;":[46,83],"CYP3A4":[47,84,126,134],"inducer)":[48],"decreased":[49],"area":[51],"under":[52],"concentration\u2010time":[54],"curve":[55],"(AUC\u03c4)":[56],"during":[57],"a":[58,191],"dosing":[59],"interval":[60],"90%":[62],"maximum":[64],"concentration":[65],"(Cmax)":[66],"75%.":[68],"Conversely,":[69],"coadministration":[70],"(200":[73,80,105],"single":[75,119],"dose)":[76],"ketoconazole":[79],"twice":[82],"inhibitor)":[85],"increased":[86,139,152],"AUC":[88],"from":[89],"time":[90],"0":[91],"to":[92,164,180],"infinity":[93],"(AUC0\u2010\u221e)":[94],"Cmax":[96,151],"422%":[98],"9%,":[100],"respectively.":[101,158],"Isavuconazole":[102],"was":[103],"coadministered":[104],"3":[107],"times":[108],"daily":[109],"for":[110,141,144,149],"2":[111],"days,":[112],"then":[113],"200":[114],"doses":[120],"midazolam":[123],"(3":[124],"mg;":[125,133],"substrate)":[127],"or":[128],"ethinyl":[129,145],"estradiol/norethindrone":[130],"(35":[131],"\u03bcg/1":[132],"substrate).":[135],"Following":[136],"coadministration,":[137],"AUC0\u2010\u221e":[138],"103%":[140],"midazolam,":[142],"8%":[143],"estradiol,":[146],"16%":[148],"norethindrone;":[150],"72%,":[154],"14%,":[155],"6%,":[157],"Most":[159],"adverse":[160,174,177],"events":[161,175,178],"were":[162,169,183],"mild":[163],"moderate":[165,195],"intensity;":[167],"there":[168],"no":[170],"deaths,":[171],"serious":[173],"leading":[179],"study":[181],"discontinuation":[182],"rare.":[184],"These":[185],"results":[186],"indicate":[187],"is":[190],"sensitive":[192],"substrate":[193],"inhibitor":[196],"CYP3A4.":[198]},"counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":12},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":7}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}